CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Link
http://www.nature.com/articles/s41417-020-00256-7.pdf
Reference146 articles.
1. Lee W, Lee JH, Jun S, Lee JH, Bang D. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells. Sci Rep. 2018;8:11879. https://doi.org/10.1038/s41598-018-30205-2
2. Tong Y, Whitford CM, Robertsen HL, Blin K, Jorgensen TS, Klitgaard AK, et al. Highly efficient DSB-free base editing for streptomycetes with CRISPR-BEST. Proc Natl Acad Sci USA. 2019;116:20366–75. https://doi.org/10.1073/pnas.1913493116
3. Kim W, Lee S, Kim HS, Song M, Cha YH, Kim YH et al. Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Res. 2018. https://doi.org/10.1101/gr.223891.117
4. Sachdeva M, Sachdeva N, Pal M, Gupta N, Khan IA, Majumdar M, et al. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther. 2015;22:509–17. https://doi.org/10.1038/cgt.2015.54
5. Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature. 2017;551:464–71. https://doi.org/10.1038/nature24644
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10
2. Application of CRISPR–Cas Technology in Drug Development;Trends in Plant Biotechnology;2024
3. Modern therapies of nonsmall cell lung cancer;Journal of Applied Genetics;2023-09-12
4. Deletion of LCMR1 in alveolar type II cells induces lethal impairment of lung structure and function in adult mice;Journal of Thoracic Disease;2023-03
5. Nano-immunotherapy for lung cancer;Nano TransMed;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3